Oncology Archives - Page 6 of 78 -

Novartis has been steadily investing in radiopharmaceuticals over the last few years, and one of those deals has

Novartis gets first OK for radioligand Pluvicto in prostate cancer

https://pharmaphorum.com/news/novartis-gets-first-ok-for-radioligand-pluvicto-in-prostate-cancer/

Sanofi backs precision oncology firm Nucleai in $33m fundraising

Phil Taylor artificial intelligence, financing, immuno-oncology, Nucleai, Oncology, precision oncology, Sanofi, spatial biology 0 Comment

Israeli startup Nucleai has raised $33 million in a second-round financing that will be used to further its

Sanofi backs precision oncology firm Nucleai in $33m fundraising

https://pharmaphorum.com/news/sanofi-backs-precision-oncology-firm-nucleai-in-33m-fundraising/

News/ News/ Oncology

Bayer backs KRAS TCR player Affini-T in $175m financing

Phil Taylor Affini-T, cell therapy, immuno-oncology, KRAS, Oncology, p53, TCR 0 Comment

Bayer’s venture capital unit has co-led a $175 million investment in Affini-T that will be used to take

Bayer backs KRAS TCR player Affini-T in $175m financing

https://pharmaphorum.com/news/bayer-backs-kras-tcr-player-affini-t-in-175m-financing/

News/ News/ Oncology

Keytruda encroaches on Jemperli’s endometrial cancer territory

Phil Taylor endometrial cancer, GlaxoSmithKline, immuno-oncology, Jemperli, Keytruda, Merck & Co, Oncology 0 Comment

Merck & Co’s KEYNOTE-158 trial of Keytruda has underpinned another FDA approval, this time for the PD-1 inhibitor

Keytruda encroaches on Jemperli’s endometrial cancer territory

https://pharmaphorum.com/news/keytruda-encroaches-on-jemperlis-endometrial-cancer-territory/

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

News/ News/ R&D

BMS buys into Volastra’s cancer expertise with $1.1bn alliance

Phil Taylor Bristol-Myers Squibb, chromosomal instability, drug discovery, Oncology, partnering, Volastra Therapeutics 0 Comment

Bristol-Myers Squibb is the first big pharma to strike a deal with Volastra Therapeutics, a start-up that has

BMS buys into Volastra’s cancer expertise with $1.1bn alliance

https://pharmaphorum.com/news/bms-buys-into-volastras-cancer-expertise-with-1-1bn-alliance/

Events/ Events/ Oncology

Welcome to the 2nd Tumor Myeloid-Directed Therapies Summit

Hollie Bulfin cancer, immuno-oncology, myeloid biology, Oncology, tumor microenvironment 0 Comment

Identify, Validate, & Clinically Develop Novel Targets to Modulate Myeloid Cells & Overcome Solid Tumor Barriers Returning in

Welcome to the 2nd Tumor Myeloid-Directed Therapies Summit

https://pharmaphorum.com/events/welcome-to-the-2nd-tumor-myeloid-directed-therapies-summit/

Market Access/ News/ News

NHS grants fast-track access to Takeda’s lung cancer drug Exkivity

Phil Taylor access, EGFR, Exkivity, NHS, Non-small cell lung cancer, Oncology, Project Orbis, Takeda 0 Comment

Takeda has secured UK approval for its lung cancer therapy Exkivity, with an NHS access deal that could

NHS grants fast-track access to Takeda’s lung cancer drug Exkivity

https://pharmaphorum.com/news/nhs-grants-fast-track-access-to-takedas-lung-cancer-drug-exkivity/

News/ News/ Oncology

Belgium’s Precirix raises €80m to fund radiopharma aspirations

Phil Taylor Belgium, Biotech, financing, Oncology, Precirix, Radiopharmaceutical 0 Comment

Precirix has raised €80 million ($88 million) in a second-round financing that will be used to advance multiple

Belgium’s Precirix raises €80m to fund radiopharma aspirations

https://pharmaphorum.com/news/belgiums-precirix-raises-e80m-to-fund-radiopharma-aspirations/

News/ News/ Oncology

Merck trial of Keytruda, Lynparza combo in prostate cancer fails

Phil Taylor AstraZeneca, immuno-oncology, Keytruda, Lynparza, Merck & Co, Oncology, Prostate cancer 0 Comment

Merck & Co’s two powerhouse oncology drugs – Keytruda and Lynparza – have failed to show efficacy when

Merck trial of Keytruda, Lynparza combo in prostate cancer fails

https://pharmaphorum.com/news/merck-trial-of-keytruda-lynparza-combo-in-prostate-cancer-fail/

Trending

Oncology

Login